Long- term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open- label extensions of two Phase 3 clinical trials. Multiple sclerosis (Houndmills, Basingstoke, England) 2. Jan. Weisfeld- Adams JD, Katz Sand IB, Honce JM, Lublin FD. Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. Brain : a journal of neurology 2. Mar; 1. 38(Pt 3). Vidaurre OG, Haines JD, Katz Sand I, Adula KP, Huynh JL, Mc. Student Insights + As a Master’s degree is now the entry level degree of students coming out of PA school, I felt it important to . After doing research of programs recommended by the AAPA and assessing. BC Children’s Hospital: Child Psychiatry. Susan Lazar, Medical Director. Adolescent Psychiatry. Jennifer Russel, Medical Director. Anna Kalenchuk CAPE Dr. Graw CA, Zhang F, Varghese M, Sotirchos E, Bhargava P, Bandaru VV, Pasinetti G, Zhang W, Inglese M, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P. Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain : a journal of neurology 2. Aug; 1. 37(Pt 8). Datta S, Staewen TD, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Narayana PA. Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi- center data. Multiple sclerosis and related disorders 2. Mar; 4(2). Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD. Safety and efficacy of fingolimod in patients with relapsing- remitting multiple sclerosis (FREEDOMS II): a double- blind, randomised, placebo- controlled, phase 3 trial. Neurology 2. 01. 4 Jun; 1. Oynhausen S, Alcauskas M, Hannigan C, Bencosme Y, M. Emergency medical care of multiple sclerosis patients: primary data from the mount sinai resource utilization in multiple sclerosis project. Journal of clinical neurology (Seoul, Korea) 2. Jul; 1. 0(3). Lublin FD. New multiple sclerosis phenotypic classification. European neurology 2. Suppl 1. Pandey KS, Lublin FD, Miller AE, Krieger SC. Clinical Course in Multiple Sclerosis Patients Presenting with a History of Progressive Disease. Multiple Sclerosis and Related Disorders 2. Lublin FD, Bowen J, Huddlestone J, Kremenchutzky J. Human Placenta- Derived Cells (PDA- 0. Treatment of Adults with Multiple Sclerosis: A Randomized, Placebo- Controlled, Multiple- Dose Study. Multiple Sclerosis and Related Disorders 2. September. Lublin FD, Cutter G, Giovannoni G, Pace a. Natalizumab Reduces Relapse Clinical Severity and Improves Relapse Recovery in MS. Multiple Sclerosis and Related Disorders 2. September. Lublin FD, Reingold SC, Cohen JA, Cutter GR, S. Defining the clinical course of multiple sclerosis: the 2. Neurology 2. 01. 4 Jul; 8. Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of neurology 2. Mar; 7. 3(3). Lublin FD. MS as a gateway disease. Journal of the neurological sciences 2. Oct; 3. 33(1- 2). O'Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson TP, Miller AE, Dive- Pouletty C, B. Teriflunomide reduces relapse- related neurological sequelae, hospitalizations and steroid use. Journal of neurology 2. Oct; 2. 60(1. 0). Narayana PA, Govindarajan KA, Goel P, Datta S, Lincoln JA, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS. Regional cortical thickness in relapsing remitting multiple sclerosis: A multi- center study. Clinical 2. 01. 2; 2. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg- Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2. Mc. Donald criteria. Annals of neurology 2. Feb; 6. 9(2). Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA. Human placenta- derived cells (PDA- 0. Multiple sclerosis and related disorders 2.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
January 2017
Categories |